Lyme Disease - Drug Pipeline Analysis and Market Forecasts to 2016

The "Lyme Disease - Drug Pipeline Analysis and Market Forecasts to 2016" report provides the key data, information and analysis on the Lyme disease market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with Lyme disease, a competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for the future market competition, and the key players in the Lyme disease market.

The Lyme Disease Market is Forecast To Grow at a Steady Rate Between 2009 and 2016

The report estimated that the Lyme disease market was worth $2.2m in 2009. The major reason for the limited market revenues is that there is no approved drug for Lyme disease treatment. Antibiotics such as doxycycline, cefuroxime and amoxicillin are currently used off-label. The patent protection of all these antibiotics expired long ago and many generic versions of the antibiotics are available very cheaply. In 2009, the annual cost of therapy for Lyme disease with antibiotics was $81. Between 2001 and 2009, the Lyme disease market grew only at a CAGR of 6.1%. The late-stage pipeline for the Lyme disease market is very weak and is entirely made up of antibiotics that are currently used as off-label drugs. Therefore, even though these drugs will receive regulatory approval for the Lyme disease market, the entry of antibiotics is expected to have a negligible impact on the market in terms of sales value and volume. Overall, between 2009 and 2016, the Lyme disease market is expected to grow at a CAGR of only 4.8% to reach $3.1m by 2016.

Global Lyme Disease Market Revenue ($m), 2001-2016

The Current Competition in the Lyme Disease Market is Strong

The report found that the current competition in the Lyme disease market is strong. The currently used antibiotics are effective against the disease. Antibiotics are normally used in the early stages of Lyme disease and the drugs effectively treat the disease with minimum side effects. Antibiotics are prescribed to be taken orally or intravenously in patients with late stage persistent Lyme disease to treat symptoms such as early arthritis, skin rashes, joint problems, late nervous system problems, or heart problems. The majority of the early-stage patients treated with antibiotics never test positive for Lyme disease again. This indicates that the market is well served by antibiotics.

The Lyme Disease Market is Well Served by the Use of Off-Label Antibiotics

The report found that the Lyme disease market is well served by the currently available off-label treatment options. The antibiotics used in Lyme disease treatment effectively treat patients and the patient compliance rate for the drugs is high. However, unmet need still exists in the Lyme disease market in terms of safety and the lack of approved vaccines. These unmet needs can be effectively addressed by vaccines that are effective and safe in treating the disease. Vaccines not only treat the patients who already have Lyme disease but also prevent normal people contracting the disease.

The report expects that two vaccines will enter the Lyme disease market after 2016. The market entry of these vaccines will positively affect the market and the market will grow at a significantly faster pace compared to the present market growth rate.

Opportunity and Unmet Need in the Lyme Disease Market, 2010

Weak Pipeline Hindering the Future Growth of the Lyme Disease Market

The report found that the pipeline in the Lyme disease market is weak. There are only five molecules in the current pipeline. Of the five molecules, 20% are in Phase III, 20% are in Phase II and the remaining 60% are in early-stage development. The late-stage clinical development pipeline is very weak. The majority of the late-stage development molecules are antibiotics being used as off-label drugs in the Lyme disease market. These molecules are very likely to receive regulatory approval. However, the entry of these drugs is not expected to have a positive impact on the Lyme disease market because the patent protection for these drugs has already expired and cheaper generic versions are widely available in the market.

The early-stage pipeline contains two vaccines. One vaccine is being developed by Baxter Vaccines while the other vaccine is being developed by Intercell AG. Preclinical studies on these vaccines reported positive results in the treatment of Lyme disease. It may take approximately seven to nine years for these drugs to enter the market. However, once they enter the market, they are expected to significantly affect the growth of the market.

Lyme Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

This new report, "Lyme Disease – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global Lyme disease market. The report identifies the key trends shaping and driving the global Lyme disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Lyme disease sector.

Scope

The scope of the report includes:
- Annualized global Lyme disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global Lyme disease market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with Lyme disease

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Lyme disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Lyme disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Lyme disease market landscape? – Identify, understand and capitalize.